Business Context and Reporting Period
Aclarion, Inc. (ACON), a Delaware corporation, filed this Form 8-K on January 17, 2025, reporting events occurring on January 15, 2025. The Company is an emerging growth company with its principal executive offices in Broomfield, Colorado. The filing details the entry into a material definitive underwriting agreement for a public offering of equity securities.
Key Financial Metrics and Transaction Details
The Company completed a public offering (the "Offering") on January 16, 2025, with Dawson James Securities, Inc. as the sole book-running manager. The Offering consisted of:
- Common Stock: 100,000 shares sold at $0.10 per unit.
- Pre-Funded Warrants: 143,900,000 warrants sold at $0.09999 per unit, exercisable immediately at $0.00001.
- Series A Common Warrants: 144,000,000 warrants (plus 21,000,000 from over-allotment) with an exercise price of $0.20, exercisable after stockholder approval, expiring in five years.
- Series B Common Warrants: 144,000,000 warrants (plus 21,000,000 from over-allotment) with an exercise price of $0.20, exercisable after stockholder approval, expiring in two and one-half years.
Proceeds: Net proceeds from the Offering were approximately $13.3 million, excluding potential proceeds from the exercise of warrants. Potential additional gross proceeds from the full cash exercise of Common Warrants are estimated at approximately $81.1 million.
Material Changes and Use of Proceeds
The primary material change is the significant capital raise and the resulting dilution from the issuance of shares and warrants. The Company intends to use the net proceeds as follows:
- Redeem all outstanding shares of Series B Preferred Stock at a price of $1,000 per share plus accrued but unpaid dividends.
- Build out product platforms.
- Expand sales and marketing efforts.
- Cover general and administrative expenses and other corporate purposes.
The filing does not provide comparative financial metrics (revenue, profit, cash flow, or margins) for the current period versus the prior period, as this is a current report regarding a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Contingencies
Stockholder Approval: The issuance of shares upon exercise of the Common Warrants is contingent upon stockholder approval under Nasdaq rules. The Company intends to hold a meeting to obtain this approval within 60 days of January 6, 2025.
Lock-Up Agreements: Directors and officers are subject to a 90-day lock-up period following the closing. The Company is restricted from issuing additional common stock or equivalents for 45 days after the stockholder approval date, with further restrictions on variable rate transactions for 90 days after approval.
Risks: There is no assurance that the Common Warrants will be exercised. The filing notes that the description of the agreements is qualified by reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the exact redemption price and total cost to redeem the Series B Preferred Stock, including accrued dividends.
- Confirm the date and outcome of the stockholder meeting required to approve the issuance of shares upon warrant exercise.
- Review the full text of the Underwriting Agreement (Exhibit 10.1) and Warrant forms (Exhibits 4.1, 4.2, 4.3) for specific covenants and limitations.
- Assess the impact of the 144,000,000+ warrants on future dilution if exercised at the $0.20 strike price.
- Monitor the Company's cash position post-redemption to ensure sufficient liquidity for product development and operations.